` 688553 (Sichuan Huiyu Pharmaceutical Co Ltd) vs Shanghai Composite Comparison - Alpha Spread
Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

688553
vs
S
Shanghai Composite

Over the past 12 months, Sichuan Huiyu Pharmaceutical Co Ltd has underperformed Shanghai Composite, delivering a return of +23% compared to the Shanghai Composite's +24% growth.

Back to 688553 Analysis

Stocks Performance
688553 vs Shanghai Composite

Loading
688553
Shanghai Composite
Add Stock
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
688553 vs Shanghai Composite

Loading
688553
Shanghai Composite
Difference
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y

Performance By Year
688553 vs Shanghai Composite

Loading
688553
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Sichuan Huiyu Pharmaceutical Co Ltd vs Peers

Shanghai Composite
688553
JEF
JNJ
4312
Add Stock
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Sichuan Huiyu Pharmaceutical Co Ltd
Glance View

Market Cap
8.1B CNY
Industry
Pharmaceuticals

Sichuan Huiyu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products. The company is headquartered in Neijiang, Sichuan and currently employs 1,480 full-time employees. The company went IPO on 2021-10-26. The Company’s products are mainly anti-tumor chemical injections, including pemetrexed disodium for injection, docetaxel injection, zoledronic acid injection, irinotecan hydrochloride injection, doxorubicin hydrochloride injection liquid and azacitidine for injection. The firm's products are mainly used in the clinical treatment of various adaptive diseases. The firm distributes its products both in the domestic market and to overseas markets.

Intrinsic Value
12.57 CNY
Overvaluation 35%
Intrinsic Value
Price
What is Intrinsic Value?
Back to Top
ALPHA SPREAD
Follow us
Join more than 320,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.